Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats by Nozaki, Yoshihiro et al.
Acta Orthopaedica 2012; 83 (1): 87–92  87
Pravastatin reduces steroid-induced osteonecrosis of the 
femoral head in SHRSP rats
Yoshihiro Nozaki1, Kenji Kumagai1, Noriaki Miyata1, and Masami Niwa2 
1Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences; 2Department of Pharmacology, Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki, Japan
Correspondence: kenjikum-ngs@umin.ac.jp   
Submitted 10-10-29. Accepted 11-09-26
Open Access - This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, 
distribution, and reproduction in any medium, provided the source is credited.
DOI 10.3109/17453674.2011.641103
Background and purpose   Although the definite cause of steroid-
induced osteonecrosis of the femoral head (ONFH) is unknown, 
peripheral circulatory failure, lipid metabolism disturbance, and 
increased oxidative stress are considered to be possible causes. We 
investigated whether pravastatin as a statin treatment reduces 
(1) the incidence of ONFH, (2) the adipocyte area, and (3) bone 
marrow changes in the femoral head. 
Methods We divided up 81 thirteen-week-old spontaneously 
hypertensive stroke-prone (SHRSP)/Izm male rats into 4 groups: 
a control group (group C), a group given pravastatin (group P), a 
group given steroid (group S), and a group given both pravastatin 
and steroid (Group PS). The steroid was administered at 15 weeks 
of age. Pravastatin, as a statin, was administered in the drinking 
water for 4 weeks. The rats were killed when 17 weeks old. Osteo-
necrosis was diagnosed based on histopathological examination. 
Oxidative stress was assessed from immunostaining.
Results   The incidence of histological osteonecrosis was lower 
in the groups given pravastatin. The percentage of adipocyte area 
in the bone marrow was lower in the PS group than in the S group. 
Immunohistochemical staining for oxidative stress showed that 
staining was less in the PS group than in the S group. Pravastatin 
had no effect on the blood-derived biochemical findings on lipid 
metabolism. However, it reduced the incidence of steroid-induced 
ONFH in these SHRSP rats. We presume that this occurred by 
reducing oxidative stress and by reducing the percentage of adi-
pocyte area in the femoral heads.
Interpretation   Our data suggest that pravastatin may be effec-
tive in reducing steroid-induced ONFH.

Every year, 3,000 of the 128 million inhabitants in Japan 
develop osteonecrosis of the femoral head (ONFH), and the 
number of patients—particularly those treated with steroid 
therapy—has been increasing over the years (Hirota et al. 
1997). The proposed pathogenesis of steroid-induced ONFH 
includes increased oxidative stress, lipid metabolism distur-
bance, and disturbances of the coagulation-fibrinolysis system 
due to steroid hormones (Fisher 1978, Cheras 1997, Ichiseki 
et al. 2004, 2006). Statins are lipid-lowering, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
(Endo 1992). Some statins have been reported to enhance the 
antioxidant activity and local lipid kinetics by directly acting 
on adipocytes and blood vessels, thus reducing the severity 
and frequency of ONFH (Cui et al. 1997, Pritchett 2001, Ich-
iseki et al. 2004, 2006, Nishida et al. 2008, Yagi et al. 2008 , 
Kuribayashi et al. 2010). 
ONFH observed in spontaneously hypertensive stroke-prone 
(SHRSP) rats closely resembles human ONFH, not only his-
tologically but also physiologically (Hirano et al. 1989, Wada 
et al. 2004, Murata et al. 2007, Suzuki et al. 2008). We have 
reported a 50% incidence of spontaneous osteonecrosis of the 
femoral head in SHRSP rats at the age of 16–18 weeks, and 
they develop ONFH more frequently (up to 90%) with steroid 
administration (Murata et al. 2007, Suzuki et al. 2008). Unlike 
rabbits, chickens, and other rats, SHRSP rats are an inbred, 
established model of ONFH.
In this work, we studied the ability of pravastatin to reduce 
the incidence of steroid -induced osteonecrosis in SHRSP 
rats. We also examined whether pravastatin could reduce the 
number of sites of osteonecrosis development in individual 
rats that developed osteonecrosis. Finally, we determined 
whether pravastatin has any effects on disorders of lipid 
metabolism and lipid peroxidation after corticosteroid admin-
istration.
Material and methods
Animals
All protocols in this study were followed in accordance with 
the guidelines of the Animal Care and Use Committee of our 
institution (date of issue: June 17, 2009; registration number: 
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and were kept in a room at 24 ± 2°C and a humidity of 55 ± 
2%. For groups P and PS, pravastatin sodium powder (Mev-
alotin; Daiichi Sankyo Co. Ltd., Tokyo, Japan) at a dose of 
15 mg/day/kg was administered in the drinking water (40–45 
mL/day) from 13 weeks of age for 4 weeks. As a steroid hor-
mone, 4 mg methylprednisolone acetate was injected subcu-
taneously into the back at 15 weeks of age (corresponding to 
1,000 mg/60 kg as a human steroid pulse therapy). The rats 
were killed at 17 weeks of age; they were first anesthetized 
with a 3-min inhalation of ether, after which they were given 
an abdominal injection of pentobarbital solution at (50 mg/kg 
weight).
Hematological examination 
Blood was collected from the heart and both femoral heads 
were removed. To investigate the hyperlipidemia-improving 
effects of pravastatin, the serum levels of total cholesterol 
(T-cho), high-density lipoprotein (HDL), low-density lipopro-
tein (LDL), and triglycerides (TG) were determined.
Tissue preparation 
The proximal portions of both femurs were fixed in 10% 
neutral buffered formalin for 24 h, decalcified using EDTA 
solutions with constant reaction time and temperature, and 
embedded in paraffin. Subsequently, 4 sections through the 
teres ligament were stained with hematoxylin and eosin.
Evaluation of osteonecrosis
The histopathological changes were examined with a light 
microscope. There was no heat generation during section 
preparation. We evaluated osteonecrosis according to our 
staging criteria based on Arlet and Durroux (1973), consisting 
of the presence or absence of fatty degeneration, myelocyte 
necrosis, osteocyte necrosis, and appositional bone formation 
(Figure 1). 
3 of us (YN, KK, and NM) evaluated all sections by ran-
domly numbering and individually examining all samples to 
minimize interobserver variability. 
Immunohistochemistry 
To detect oxidative stress, specimens were reacted with anti-
8-hydroxydeoxyguanosine (anti-8-OHdG) and anti-4-hy-
droxy-2-nonenal (anti-4-HNE) monoclonal antibodies (NOF 
Corp, Tokyo, Japan) as primary antibodies for the oxidative 
stress assay, followed by staining with a Vectastain ABC Kit 
(Vector Laboratories, Burlingame, CA) according to the man-
ufacturer’s instructions. Anti-4-HNE monoclonal antibody 
detects 4-HNE, which is a secondary product of the oxidation 
of w-6 polyunsaturated fatty acids, particularly around adipose 
cells. Use of the anti-8-OHdG monoclonal antibody is based 
on the fact that when oxidative stress due to active oxygen 
species is increased, 8-OHdG is formed in DNA and detected 
in the nucleus. When evaluating the staining for 4-HNE and 
8-OHdG, the intensity of staining was also considered. To 
detect oxidative stress, we examined 20 sections by randomly 
selecting 5 femoral heads, from separate rats, from each of 
the 4 groups. Furthermore, to objectively evaluate the find-
ings, we evaluated the staining of cells and surrounding struc-
tures in these sections: in the blood vessels, adipocytes, bone 
marrow cells, and trabeculae in each group using a 3-point 
scale (negative, positive, and intensely positive) and calculat-
ing the mean total scores by a “3-point method”. Also, the 
images were examined blind, and the scores were averaged 
among the observers. 3 of the authors (YN, KK, and NM) 
examined all the immunochemical sections and scored them 
using the 3-point method.
Figure 1. Illustration of histological criteria for ONF. The photomicrographs illustrate 
normal bone (A, F), fatty degeneration (B, G), early necrosis (C, H), fresh necrosis (D, 
I), and old necrosis (E, J) (stain: hematoxylin and eosin). The upper row shows whole 
femoral head (original magnification: ×20) and the lower row shows key findings of 
each category at high magnification. The fatty degeneration stage has fatty degenera-
tion in the bone marrow (G), the early necrosis stage has myelocyte necrosis in bone 
marrow (H), the fresh necrosis stage has osteocyte necrosis (I), and the old necrosis 
stage has appositional bone formation (J).
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We used male SHRSP/Izm rats (SHR Coop-
erative Research Association, Hamamatsu, Japan) 
at 13 weeks of age. From our previous results 
of osteonecrosis frequencies, to detect at least a 
50% difference between treatment groups (40% in 
the control group and 90% in the steroid group) 
with a power of 80% (α = 0.05) (Aoki 2004), we 
determined that 14 animals would be required in 
the S and PS groups. Multiple comparisons were 
not considered when calculating the sample size. 
Thus, the real statistical power may have been 
less than 80%. Rats were divided into 4 groups: a 
control group (group C, 28 rats), a steroid-admin-
istered group (group S, 23 rats), a pravastatin-
administered group (group P, 14 rats), and a group 
given pravastatin and steroid (group PS, 15 rats). 
More rats were allotted to groups C and S to allow 
us to become familiar with the experimental pro-
cedure, but we present the data from all the rats. 
The rats were housed in standard rat cages at the 
animal center; they were fed a semipurified diet Acta Orthopaedica 2012; 83 (1): 87–92  89
Measurement of the adipose area in bone marrow 
To measure the percentage of adipose area in the bone marrow, 
we used a camera connected to an image processor, according 
to the procedure of Nishida et al. (2008). The area of the bone 
marrow and adipose cells displayed on the video monitors was 
measured using an interactive mouse pad-tracing instrument 
(NIH Image software program; NIH, Bethesda, MD).
Statistics 
All statistical analyses were performed using SAS software 
version 9.1.3 (SAS Institute Inc., Cary, NC). Data were 
expressed as mean (SD). To detect differences in the inci-
dence of ONFH between the groups, we used generalized 
estimating equations (GEEs), a method that allows inclusion 
of correlated observations, in this case between the right and 
left heads (Park et al. 2010). For comparisons of means among 
multiple groups, a general linear modeling method (ANOVA) 
and Tukey’s method for multiple comparisons were used for 
continuous variables.
Results
Osteonecrosis 
We analyzed 160 femoral heads in 80 rats (Table 1). The inci-
dence of histological ONFH was higher in group S than in 
group C (p < 0.001), and lower in group PS than in group 
S (p < 0.001), indicating that pravastatin markedly inhibits 
ONFH. The inter-observer variability was about 10%.
Adipose area in bone marrow
5 femoral heads, which were not from the same rat, were 
randomly selected from each of the 4 groups. Of these, the 
percentage of adipocyte area was higher in group S (33% (SD 
9)) than in groups C (3% (SD 3)), P (6% (SD 7)), and PS (11% 
(SD 5)) (Figure 2). Thus, the adipocyte area was reduced by 
about 20% as a result of pravastatin treatment. The fact that 
the percentage in group PS was statistically significantly 
smaller than that in group S appears to indicate that pravas-
tatin reduced the effect of steroid. 
Oxidative stress
When oxidative stress was compared using staining with 
anti-4-HNE and anti-8-OHdG monoclonal antibodies, simi-
lar tendencies with weaker changes were observed with anti-
8-OHdG. In group S, the adipose cell and myelocytes were 
strongly stained and some osteocytes were also stained. The 
staining in the adipose cells was not diffuse, but was localized 
around the membrane. In the PS group, staining of the adipose 
cell membrane was weaker than that in the S group. In the 
C and P groups, little or no staining for oxidative stress in 
the adipose cell membrane was observed. These findings were 
more obvious from the results of the 3-point method (Figure 
3). 
Thus, it appears that bone marrow changes can be sup-
pressed (by about 5%) by pravastatin treatment. The scoring 
by the 3 observers was consistent.
Vascular damage
The vascular damage was assessed from hematoxylin and 
eosin-based histological data from the 4 groups. No statistically 
significant changes were observed between groups.
Body weight, laboratory data, and blood pressure. 
There was no statistically significant difference in blood pres-
sure between groups C and S; the mean values were the same 
(284 Torr in both groups). Pravastatin administration caused 
Incidence of histological ONFH with pravastatin. Mean (SD)
Pravastatin –  –  +  +
Steroid  – +  – +
Group  C S  P PS
  (n = 28)  (n = 23)  (n = 14)  (n = 15)
Necrosis, n (%)
  0  13 (46)     0 (0)  10 (71)     4 (27)
  1  13 (46)     4 (17)    3 (21)     9 (60)
  2    2 (7)   19 (83)    1 (7)     2 (13)
p-value    < 0.001 a    0.3 a  < 0.001 b 
             0.05 c
 
a compared with group C.
b compared with group S.
c compared with group P.
Figure 2. Area of adipocytes in the bone marrow. The pictures in the 
upper row show that the adipocyte area in the bone marrow of the 
femoral head epiphysis was larger in group S (panel C) than in groups 
PS (panel D), C (panel A), or P (panel B) (stain: hematoxylin and eosin; 
original magnification: ×100). In the lower panel, the percentage area 
of adipocyte tissue in the bone marrow is compared for the 4 groups 
(see Results). Error bars indicate SD. a p < 0.001 (Fisher’s exact test).
a
aa
30
20
10
0
40
50
ContP SP S
Area of adipocyte tissue (%)
 Control  P  S  PS90  Acta Orthopaedica 2012; 83 (1): 87–92
weight loss (mean 314 g in group C vs. 281 g in group P), 
but the rats grew normally. None of the rats died due to the 
steroid administration. Steroid loading resulted in substantial 
weight loss (mean 314 g in group C vs. 246 g in group S). 
Blood chemistry data showed that steroid hormone adminis-
tration (group S) induced marked hyperlipidemia, that is, sig-
nificantly elevated total cholesterol levels (mean 60 mg/dL in 
group C vs. 104 mg/dL in group S), HDL levels (mean 18 mg/
dL in group C vs. 30 mg/dL in group S), LDL levels (mean 8.3 
mg/dL in group C vs. 16 mg/dL in group S), and triglyceride 
levels (mean 40 mg/dL in group C vs. 102 mg/dL in group S) 
relative to the C group (p < 0.05 in all cases). Administration 
of pravastatin in combination with the steroid hormone did not 
reduce hyperlipidemia or total cholesterol. 
Discussion
Circulatory disturbance, impairment of lipid metabolism, and 
increased oxidative stress have been suggested to be involved 
in the etiology of steroid-induced ONFH. Many drugs to 
inhibit these have been tested in animals and humans, result-
ing in reports of prevention or suppression of the progression 
of ONFH by the administration of warfarin, low-molecular-
weight heparin, statins, and vitamin E (Pritchett 2001, Glueck 
et al. 2005, Mont et al. 2006, Nagasawa et al. 2006, Kurib-
ayashi et al. 2010). Glueck et al. (2005) studied 224 patients: 
26 patients with multifocal osteonecrosis, 91 patients with 
unifocal osteonecrosis, and 117 control patients. They found 
that osteonecrosis was associated with familial thrombophilia 
and eNOS T-786C polymorphism. 
Statins (HMG-CoA reductase inhibitors) have been widely 
used to treat hyperlipidemia (Endo 1992). In a clinical study 
of 284 patients with statin, Pritchett (2001) observed improve-
ment in hyperlipidemia and lower incidence of osteonecrosis 
in patients who were on high-dose steroid treatment, com-
pared with the control group. That study was retrospective, 
so whether the high lipid level was a cause of—or merely 
associated with—the osteonecrosis is unclear. Furthermore, 
Jasiñska et al. (2007) reported pleiotropic (multiphasic) effects 
of statins such as increased upregulation of eNOS and nitric 
oxide production. We selected a hydrophilic statin as a pro-
phylactic agent for ONFH in the present study using SHRSP 
rats.
Our study has some limitations. First, there have been few 
studies using rats. However, the rats we used were of a pure 
strain that we have used in various studies, with consistent 
results. This also contributed to simplification of the study 
design. Various animal species have been used as experimen-
tal models of steroid-induced ONFH, including rabbits, dogs, 
birds including the emu, and sheep (Li et al. 2009). The SHR 
rats were developed in 1959 by Okamoto et al., and not only 
have hypertension but also peripheral circulatory failure (Oka-
moto 1969, Yamori 1984).
We have conducted research using SHRSP for over 20 
years, and have found that the pathology of ONFH in this 
model resembles that in humans more closely, being localized 
in the femoral head, than in the more commonly used rabbits 
(Murata et al. 2007, Suzuki et al. 2008). The second limitation 
is the extrapolation from rats to humans, and the third is that 
our study involved a single observation point. As SHRSP rats 
are very sensitive to stimulation, multiple blood drawing is 
dangerous for the animals. Also, we considered that a sero-
logical comparison between the groups at a single observation 
point was possible because they are a pure strain of rats that 
has uniform characteristics. Finally, we used a water-soluble 
statin, so that the doses of pravastatin could be easily adjusted 
by dissolving it in drinking water. Multiple feedings or injec-
tions are dangerous for SHRSP rats because of their sensitiv-
ity. The stronger statins, such as lovastatin, were not suitable 
for use with SHRSP rats because they have been reported to be 
insoluble in water (Cui et al. 1997, Li et al. 2003). 
Our findings provide further evidence that a statin can sup-
press steroid-induced ONFH in rats. Nishida et al. (2008) 
reported that a statin reduced the incidence of steroid-induced 
ONFH by one third. However, Fujioka et al. (1997) found that 
cholesterol synthesis in the rat liver increased after 7 days of 
consecutive administration of pravastatin, and suggested that 
induced HMG-CoA reductase activity overcomes the inhibi-
tory effects of pravastatin, resulting in an increase in net cho-
lesterol synthesis in rats, but not in rabbits. According to our 
histological results, the area of bone marrow occupied by adi-
pocytes was reduced by about one fifth, which we interpret as 
a sign of improvement in local lipid metabolism by pravastatin 
treatment. Kuribayashi et al. (2010) also found that there is a 
decrease in local lipid levels after vitamin E administration, 
even without any reduction in lipid levels in blood tests.
Figure 3. Comparison of oxidative stress (4-HNE). Very strong immu-
nostaining was observed in group S (A, B), but the staining was very 
weak in group PS (D, E) in comparison. Magnification: ×20 (A, D), ×100 
(B, E). C. Strong immunostaining in marrow cells, around adipocytes, 
and in vessel walls in group S. Magnification: ×200. F. The strongest 
staining was observed in group S, followed by group PS, group C, and 
group P with the 3-point method. Error bars indicate SD. a p < 0.001 
(Fisher’s exact test).
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Nishida et al. (2008) noted that not only LDL-lowering 
effects but also non-lipid effects of pitavastatin contributed to 
the prevention of ONFH by reducing the formation of thrombi 
and lipid emboli in bone marrow blood vessels. In a study of 
the action of statins on adipocytes in bone marrow, Li et al. 
(2003) reported that lovastatin inhibits adipocyte differentia-
tion, apparently by acting on the expression of the fat cell-spe-
cific genes PPARγ2 and 422aP2 and subsequent maturation. 
Cui et al. (1997) suggested that lovastatin prevents the effects 
of steroids on adipogenesis and the expression of fat-specific 
gene 422 (aP2), and attenuates the inhibitory effects of ste-
roids on osteoblastic gene expression in cultured cells and 
adipogenesis and osteonecrosis in chickens. Yagi et al. (2008) 
reported that pitavastatin may reduce the oxidative stress 
induced by reduced nitric oxide bioavailability, and thereby 
prevent vascular endothelial injury caused by excess cortico-
steroids—thus being an effective pleiotropic inhibitor of the 
development of ONFH.An increase in oxidative stress due to 
steroid administration can be detected immunohistologically, 
but changes were demonstrated numerically in this study. 
The reduction in oxidative stress and incidence of ONFH by 
the statin may have occurred by chance in the present study, 
but many researchers have recently detected oxidative stress 
at the sites of ONFH or have demonstrated suppression of 
osteonecrosis by an antioxidant agent. Ichiseki et al. (2004, 
2006) reported that ONFH could be suppressed by control-
ling oxidative stress in rabbits and rats, and Kuribayashi et al. 
(2010) described the prevention of ONFH in rabbits by the 
antioxidant action of vitamin E at a dose that has no effect on 
lipid metabolism. Some reports have mentioned the oxidative 
stress-induced endothelial dysfunction and ischemic change 
in SHR vessels (Nakamura et al. 2007, Yao et al. 2007). It is 
still not clear which has a greater effect on inducing ONFH—
oxidative stress in adipocytes or in vessels—so further investi-
gation will be necessary.
Our preliminary data from this rat model suggest that 
pravastatin, a water-soluble HMG-CoA reductase inhibitor, 
may be useful in reducing steroid-induced ONFH. 
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